The 2022 Assisi Think Tank Meeting: white paper on optimising radiation therapy for breast cancer
dc.contributor.authorid | 0000-0002-3170-5826 | |
dc.contributor.coauthor | Aristei, C. | |
dc.contributor.coauthor | Kaidar-Person, O. | |
dc.contributor.coauthor | Boersma, L. | |
dc.contributor.coauthor | Leonardi, M. C. | |
dc.contributor.coauthor | Offersen, B. | |
dc.contributor.coauthor | Franco, P. | |
dc.contributor.coauthor | Arenas, M. | |
dc.contributor.coauthor | Bourgier, C. | |
dc.contributor.coauthor | Pfeffer, R. | |
dc.contributor.coauthor | Kouloulias, V | |
dc.contributor.coauthor | Meattini, I | |
dc.contributor.coauthor | Coles, C. | |
dc.contributor.coauthor | Luis, A. Montero | |
dc.contributor.coauthor | Masiello, V. | |
dc.contributor.coauthor | Palumbo, I. | |
dc.contributor.coauthor | Morganti, A. G. | |
dc.contributor.coauthor | Perrucci, E. | |
dc.contributor.coauthor | Tombolini, V. | |
dc.contributor.coauthor | Krengli, M. | |
dc.contributor.coauthor | Marazzio, F. | |
dc.contributor.coauthor | Trigo, L. | |
dc.contributor.coauthor | Borghesi, S. | |
dc.contributor.coauthor | Ciabattoni, A. | |
dc.contributor.coauthor | Ratosa, I. | |
dc.contributor.coauthor | Valentini, V. | |
dc.contributor.coauthor | Poortmans, P. | |
dc.contributor.department | N/A | |
dc.contributor.kuauthor | Bölükbaşı, Yasemin | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.yokid | 216814 | |
dc.date.accessioned | 2025-01-19T10:29:29Z | |
dc.date.issued | 2023 | |
dc.description.abstract | The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1-2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1-3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT-IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation. | |
dc.description.indexedby | WoS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.openaccess | hybrid, Green Published | |
dc.description.publisherscope | International | |
dc.description.volume | 187 | |
dc.identifier.doi | 10.1016/j.critrevonc.2023.104035 | |
dc.identifier.eissn | 1879-0461 | |
dc.identifier.issn | 1040-8428 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85160571618 | |
dc.identifier.uri | https://doi.org/10.1016/j.critrevonc.2023.104035 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/25877 | |
dc.identifier.wos | 1059240000001 | |
dc.keywords | Breast cancer | |
dc.keywords | Radiation therapy | |
dc.keywords | Combined modality treatment | |
dc.keywords | Immunotherapy | |
dc.keywords | Re-irradiation in relapsed patients | |
dc.language | en | |
dc.publisher | Elsevier Science Inc | |
dc.source | Critical Reviews in Oncology Hematology | |
dc.subject | Oncology | |
dc.subject | Hematology | |
dc.title | The 2022 Assisi Think Tank Meeting: white paper on optimising radiation therapy for breast cancer | |
dc.type | Review |
Files
Original bundle
1 - 1 of 1